EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Vyome Holdings (HIND) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Vyome Holdings $0.20, price $1.91, upside -89.5%, quality 23 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US92943X1046

VH Vyome Holdings logo Thin data Sep 24, 2026

Vyome Holdings

HIND · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.2000 · Strongly overvalued (−89.5%)
!Quality 23/100
!Weak Growth (revenue 5y −51.0 %/yr)
!negative free cash flow
!Trails peers (0/5)
!Narrow moat 23/100
!Evidence only low, so the estimate is less certain
Watch Vyome Holdings for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$1,000,000 $1.89 Fair Value $0.2000 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $1.89 – $1,000,000 · fair‑value band $0.1300 – $0.2500 · the $1.91 price screens above the $0.2000 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Vyome in your weekly email

Every Wednesday you see whether Vyome is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.

Show more

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.

Stock analysis

Vyome Holdings (HIND) currently trades at $1.91, while our model-based Fair Value estimate is $0.2000, 89.5% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 80/100, which puts the evidence level at low.

Scenario range: $0.1300 (bear) to $0.2500 (bull), the price of $1.91 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Vyome Holdings reported revenue of $320K in FY2025 versus $13.6M in FY2021, a compound −60.8%/yr. Reported net income was −$10.3M in FY2025.

Key figures

Market cap $15.3M · EPS (TTM) $−1.56 · Return on equity −999% · Return on assets (EBIT) −138% · Operating margin −3,200% · Revenue (TTM) $130K · Revenue growth (YoY) −46.0% · Free cash flow −$3.7M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 70% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −90%, HIND screens richer than that median.

Fair Value models

Bear $0.1300 Fair Value $0.2000 Bull $0.2500
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.1700 $0.2300 $0.3500 51
All 1 models by family
Asset-Based
NCAV (Graham) $0.1700 $0.2300 $0.3500 51

Open the full fair value analysis →

Notify me when HIND reaches fair value

Put HIND on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 23/100

Of which business quality 22 · Market factors (momentum, volatility) 8

Profitability 1
Margins and returns on capital today
Quality Growth 13
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 44
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 19
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−96.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−69.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−51.0%
Start year 2020 (pandemic). Over 10 years: +0.9% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−110.2% (2020) → −859.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

HIND screens overvalued: fair value 90% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Vyome Holdings with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks

Beats the industry median on 0/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 22 · Bottom 25%
Fair Value upside −89.6% · Bottom 25%
Profitability
Return on assets −48.8% · Bottom 25%
Growth and dividend
Revenue growth −46.0% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 6.27× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Vyome Holdings · Fair Value
$0.2000 −90%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Vyome Holdings Fair Value". https://www.fairvalue-calculator.com/stock/HIND

Frequently asked questions

Is Vyome Holdings (HIND) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.2000 versus a price of $1.91, about −90% upside (overvalued).
What is the fair value of HIND?
Our model-based fair value for Vyome Holdings is $0.2000 (as of Sep 24, 2026), built from audited fundamentals. The current price: $1.91.
What is the quality score of HIND?
Vyome Holdings has a Quality Score of 23/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vyome Holdings (HIND)?
Our model-based price target is the fair value of $0.2000 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $0.1300, optimistic scenario $0.2500. It is a calculation from audited fundamentals, not an analyst target.
What is the Vyome Holdings stock forecast for 2026?
Our models put fair value at $0.2000, about −90% upside versus a price of $1.91 (overvalued). Cautious scenario $0.1300, optimistic scenario $0.2500. The calculation is refreshed regularly with new filings.
What is the revenue of Vyome Holdings (HIND)?
Vyome Holdings reported trailing-twelve-month revenue of about $130K (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Vyome Holdings (HIND)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vyome Holdings it is $0.2000 per share (as of Sep 24, 2026), against a price of $1.91. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Vyome Holdings stock overvalued or undervalued in 2026?
As of Sep 24, 2026, HIND trades above its calculated fair value: price $1.91, fair value $0.2000, a gap of about −90% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HIND?
No. The price is what the market pays today ($1.91); the fair value is what the company's own numbers justify ($0.2000). For Vyome Holdings the two are $1.71 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vyome Holdings worth?
The market values Vyome Holdings at about $15.3M (market capitalisation, as of Sep 24, 2026). Per share that is $1.91; our models calculate a fair value of $0.2000 per share.
What do the bullish and bearish scenarios say about HIND?
Our models span a range for Vyome Holdings: cautious scenario $0.1300, base $0.2000, optimistic $0.2500 per share (as of Sep 24, 2026, price $1.91). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is HIND from its 52-week high?
Vyome Holdings trades at $1.91, about 70% below its 52-week high of $6.31 and 1% above the low of $1.89 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2000 is for.
Which stocks are comparable to Vyome Holdings?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vyome Holdings stock attractive at the current price?
The data as of Sep 24, 2026: price $1.91, calculated fair value $0.2000 (−90%), Quality Score 23/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HIND calculated?
We run Vyome Holdings through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.2000, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Vyome Holdings itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vyome Holdings (HIND)?
The closing price on Oct 2, 2026 was $1.91. Our model-based fair value is $0.2000, about −90% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vyome Holdings right now?
The price sits above even our optimistic bull case ($0.2500). The favourable scenario is already priced in. Weak quality (23/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.1300 to $0.2500) leaves room in how you read the outcome.

Key figures of Vyome Holdings

How large is the market capitalisation of Vyome Holdings (HIND)?
The market capitalisation of Vyome Holdings is $15.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Vyome Holdings (HIND)?
Earnings per share at Vyome Holdings are $−1.56. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Vyome Holdings (HIND)?
The return on equity (ROE) of Vyome Holdings is −999% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vyome Holdings (HIND)?
On an EBIT basis the return on assets of Vyome Holdings is −138% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vyome Holdings (HIND)?
The operating margin of Vyome Holdings is −3,200% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vyome Holdings (HIND)?
Revenue at Vyome Holdings is growing −46.0% versus a year earlier (3y avg −69.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Vyome Holdings (HIND) generate?
The free cash flow of Vyome Holdings is −$3.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Vyome Holdings (HIND) hold?
Vyome Holdings holds more cash than debt, $5.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Vyome Holdings in the live analysis

One click puts Vyome Holdings on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.